Group One Trading
RUBY

Group One Trading’s Rubius Therapeutics, Inc RUBY Stock Holding History

Group One Trading’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,500
Closed -$2K – 8402
2022
Q3 		$2K Sell
3,500
-13,800
-80% -$10.3K ﹤0.01% 7245
2022
Q2 		$15K Sell
17,300
-500
-3% -$839 ﹤0.01% 6539
2022
Q1 		$98K Buy
17,800
+17,300
+3,460% +$110K ﹤0.01% 5511
2021
Q4 		$5K Sell
500
-30,300
-98% -$420K ﹤0.01% 7671
2021
Q3 		$551K Sell
30,800
-32,200
-51% -$700K ﹤0.01% 4085
2021
Q2 		$1.54M Buy
63,000
+11,500
+22% +$288K ﹤0.01% 2915
2021
Q1 		$1.36M Buy
51,500
+21,600
+72% +$315K ﹤0.01% 2877
2020
Q4 		$227K Buy
+29,900
New +$178K ﹤0.01% 3970

Other funds holding RUBY

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return

Group One Trading's RUBY Position: Q1 2023 in Review

Group One Trading sold out of Rubius Therapeutics, Inc (RUBY) in Q1 2023, closing a stake of 9,920 shares — an estimated $1.71K sold.

Group One Trading first reported a position in RUBY in Q4 2021 and held it in 5 quarters. The position peaked at $170K in Q1 2022. 7 funds tracked by Wall St. Rank hold RUBY as of Q1 2023.

  • Group One Trading reported no remaining Rubius Therapeutics, Inc position as of Q1 2023 after selling out during the quarter.
  • Group One Trading sold 9,920 Rubius Therapeutics, Inc shares in Q1 2023, an estimated $1.71K.
  • Group One Trading first reported a position in Rubius Therapeutics, Inc in Q4 2021 and held it in 5 quarters.
  • Group One Trading's Rubius Therapeutics, Inc position peaked at $170K in Q1 2022.
  • 7 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q1 2023.

Based on Group One Trading's 13F filing for Q1 2023, filed 12 May 2023.